Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
September 01 2022 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology
company focused on the development of next generation nucleic acid
therapies targeting RNA to address both genetic and non-genetic
neurological disorders and hair loss disorders, today announced
that CEO Matthias Schroff will provide a live presentation at the
2022 Chardan Genetic Medicines Conference, occurring October 3-4,
2022.
The presentation will be available for on-demand viewing using
the virtual conference link beginning October 3, 2022 at 4:00 PM
EST and will be archived for 120 days:
https://wsw.com/webcast/chard14/xcur/1943406
Exicure will be taking 1x1 investor meetings with registered
conference attendees.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing
nucleic acid therapies targeting ribonucleic acid against validated
targets to neurological disorders and hair loss. The team includes
a diverse scientific group with expertise in nucleic acid
chemistry, drug development and neuroscience. Headquartered in
Chicago, Illinois, the Company conducts its discovery and
development efforts in-house with a dedicated 30,000 square foot
facility, including rapid and automated high throughput nucleic
acid synthesis and screening. For further information, see
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220901005015/en/
Media: Karen Sharma MacDougall 781-235-3060
ksharma@macdougall.bio
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Aug 2023 to Aug 2024